adrenomedullin pegol (BAY 1097761) / Bayer - LARVOL DELTA

SEAL: This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b | N=90 | Terminated | Sponsor: Bayer | N=466 ➔ 90 | Trial completion date: Dec 2024 ➔ Dec 2022 | Active, not recruiting ➔ Terminated | Trial primary completion date: Nov 2024 ➔ Dec 2022; Terminated (based on Part A results, Bayer decided to not continue investigating BAY 1097761 further in Part B; this was not due to any safety data for BAY 1097761)

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

SEAL: This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b | N=466 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

SEAL: This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b | N=466 | Recruiting | Sponsor: Bayer | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: May 2024 ➔ Nov 2024

Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b; N=466; Recruiting; Sponsor: Bayer; Trial completion date: Aug 2023 ➔ Jun 2024; Trial primary completion date: Jul 2023 ➔ May 2024

Clinical • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b; N=466; Recruiting; Sponsor: Bayer; Trial completion date: Feb 2023 ➔ Aug 2023; Trial primary completion date: Jan 2023 ➔ Jul 2023

Clinical • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Effects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P; N=466; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Respiratory Distress Syndrome • Respiratory Diseases

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Effects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P; N=466; Not yet recruiting; Sponsor: Bayer

Clinical • New trial • Acute Respiratory Distress Syndrome • Respiratory Diseases

This study collects information on the safety of inhaled pegylated adrenomedullin (PEG-ADM), how the drug is tolerated and how it effects patients suffering from a type of lung failure that cause fluid to build up in the lungs making breathing difficult (ARDS) Tato studie shromažďuje informace o bezpečnosti inhalovaného pegylovaného adrenomedulinu (PEG-ADM), jak je léčivo toler (clinicaltrialsregister.eu) - P2; N=466; Ongoing; Sponsor: Bayer AG

Clinical • New P2 trial • Acute Respiratory Distress Syndrome • Respiratory Diseases